KR101333279B1 - 약학적 응용을 위한 건조된 재구성 소포 형성 - Google Patents

약학적 응용을 위한 건조된 재구성 소포 형성 Download PDF

Info

Publication number
KR101333279B1
KR101333279B1 KR1020097009193A KR20097009193A KR101333279B1 KR 101333279 B1 KR101333279 B1 KR 101333279B1 KR 1020097009193 A KR1020097009193 A KR 1020097009193A KR 20097009193 A KR20097009193 A KR 20097009193A KR 101333279 B1 KR101333279 B1 KR 101333279B1
Authority
KR
South Korea
Prior art keywords
protein
liposomes
lipid
liposome
dried
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097009193A
Other languages
English (en)
Korean (ko)
Other versions
KR20090086397A (ko
Inventor
클라우스 헬러브란트
안드레아스 쉬쯔
라이너 지겔
Original Assignee
에스씨아이엘 테크놀로지 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스씨아이엘 테크놀로지 게엠베하 filed Critical 에스씨아이엘 테크놀로지 게엠베하
Publication of KR20090086397A publication Critical patent/KR20090086397A/ko
Application granted granted Critical
Publication of KR101333279B1 publication Critical patent/KR101333279B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020097009193A 2006-10-06 2007-10-05 약학적 응용을 위한 건조된 재구성 소포 형성 Expired - Fee Related KR101333279B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06021093.7 2006-10-06
EP06021093 2006-10-06
PCT/EP2007/008659 WO2008040556A1 (en) 2006-10-06 2007-10-05 Dried reconstituted vesicle formation for pharmaceutical application

Publications (2)

Publication Number Publication Date
KR20090086397A KR20090086397A (ko) 2009-08-12
KR101333279B1 true KR101333279B1 (ko) 2013-11-27

Family

ID=38910893

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097009193A Expired - Fee Related KR101333279B1 (ko) 2006-10-06 2007-10-05 약학적 응용을 위한 건조된 재구성 소포 형성

Country Status (17)

Country Link
US (3) US20090297580A1 (https=)
EP (2) EP2081551B1 (https=)
JP (2) JP5484059B2 (https=)
KR (1) KR101333279B1 (https=)
CN (3) CN102940878A (https=)
CA (1) CA2664637C (https=)
CY (1) CY1113934T1 (https=)
DK (1) DK2081551T3 (https=)
ES (2) ES2400162T3 (https=)
HR (1) HRP20130328T1 (https=)
PL (1) PL2081551T3 (https=)
PT (1) PT2081551E (https=)
RS (1) RS52706B (https=)
RU (1) RU2443412C2 (https=)
SI (1) SI2081551T1 (https=)
TW (1) TWI455731B (https=)
WO (2) WO2008040557A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6907884B2 (en) 2002-09-30 2005-06-21 Depay Acromed, Inc. Method of straddling an intraosseous nerve
US7258690B2 (en) 2003-03-28 2007-08-21 Relievant Medsystems, Inc. Windowed thermal ablation probe
US8361067B2 (en) 2002-09-30 2013-01-29 Relievant Medsystems, Inc. Methods of therapeutically heating a vertebral body to treat back pain
US7879103B2 (en) 2005-04-15 2011-02-01 Musculoskeletal Transplant Foundation Vertebral disc repair
US7959683B2 (en) 2006-07-25 2011-06-14 Musculoskeletal Transplant Foundation Packed demineralized cancellous tissue forms for disc nucleus augmentation, restoration, or replacement and methods of implantation
CA2957010C (en) 2008-09-26 2017-07-04 Relievant Medsystems, Inc. Systems and methods for navigating an instrument through bone
US10028753B2 (en) 2008-09-26 2018-07-24 Relievant Medsystems, Inc. Spine treatment kits
CA2790436A1 (en) 2010-02-18 2011-08-25 Osiris Therapeutics, Inc. Immunocompatible chorionic membrane products
SG10201502398RA (en) * 2010-04-27 2015-05-28 Scil Technology Gmbh Stable MIA/CD-RAP formulations
WO2013101772A1 (en) 2011-12-30 2013-07-04 Relievant Medsystems, Inc. Systems and methods for treating back pain
US20130202682A1 (en) * 2012-01-24 2013-08-08 The Trustees Of Columbia University In The City Of New York Synthetic matrix vesicles for biomimetic mineralization
SI2854769T1 (sl) * 2012-07-05 2023-09-29 Taiwan Liposome Company, Ltd. Postopki za zdravljenje artritisa
US10588691B2 (en) 2012-09-12 2020-03-17 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
CA2889478C (en) 2012-11-05 2020-11-24 Relievant Medsystems, Inc. Systems and methods for creating curved paths through bone and modulating nerves within the bone
US9724151B2 (en) 2013-08-08 2017-08-08 Relievant Medsystems, Inc. Modulating nerves within bone using bone fasteners
US10159646B2 (en) * 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US8986732B2 (en) 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
KR102190157B1 (ko) * 2014-12-18 2020-12-14 브라코 스위스 에스.에이. 표적화된 기체-충전 미세소포 제형
AU2016256979B2 (en) 2015-05-04 2021-01-28 Genfit Method for preparing transmembrane pH-gradient vesicles
CA2998665A1 (en) * 2015-09-18 2017-03-23 Bionet Pharma Gmbh Improvement of expression and folding in the manufacturing process of cd-rap by using a cd-rap precursor protein
US20190111178A1 (en) * 2016-04-04 2019-04-18 Gu Ventures Ab Methods and compositions for the treatment of intervertebral disc herniation
CA3061205A1 (en) * 2017-04-25 2018-11-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues
CN111182889A (zh) 2017-08-28 2020-05-19 美商Tlc生物医药公司 缓释麻醉剂组成物及其制备方法
WO2019055901A1 (en) 2017-09-18 2019-03-21 North Carolina State University ARTIFICIAL β CELLS AND METHODS OF USE
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
KR102058961B1 (ko) 2018-07-28 2019-12-24 주식회사 엑소코바이오 엑소좀의 동결건조 방법
KR102163806B1 (ko) * 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
HRP20240586T1 (hr) * 2018-10-09 2024-07-19 The University Of British Columbia Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima
EP4027912B1 (en) 2019-09-12 2024-12-18 Relievant Medsystems, Inc. Systems for tissue modulation
WO2022011115A1 (en) 2020-07-10 2022-01-13 Relievant Medsystems, Inc. Vertebral denervation in conjunction with vertebral fusion
US12082876B1 (en) 2020-09-28 2024-09-10 Relievant Medsystems, Inc. Introducer drill
AU2021409967A1 (en) 2020-12-22 2023-08-03 Relievant Medsystems, Inc. Prediction of candidates for spinal neuromodulation
US12433668B1 (en) 2021-11-08 2025-10-07 Relievant Medsystems, Inc. Impedance stoppage mitigation during radiofrequency tissue ablation procedures
CN113995852B (zh) * 2021-11-08 2024-01-30 河北大学 Arg-脂质体微囊、微囊包封的鱼精蛋白-siRNA复合体及其制备方法和应用
CN221431621U (zh) * 2023-07-10 2024-07-30 常州富谦生物科技有限公司 一种多层膜结构

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6242733A (ja) * 1985-08-07 1987-02-24 スミスクライン・ビーチャム・コーポレイション リポソ−ム形成用組成物および形成方法
JPH11514349A (ja) * 1995-09-07 1999-12-07 オッパーバス・ホールディング・ビー・ブイ 核酸デリバリー担体

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (https=) * 1977-08-05 1981-02-13 Battelle Memorial Institute
FR2416008A1 (fr) * 1978-02-02 1979-08-31 Oreal Lyophilisats de liposomes
FR2591105B1 (fr) * 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
US4897353A (en) * 1986-03-13 1990-01-30 University Of Southwestern Louisiana Cryogenic protection of phosphofructokinase using amino acids and zinc ions
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
WO1992002208A1 (en) 1990-08-08 1992-02-20 Liposome Technology, Inc. Stable doxorubicin/liposome composition
CA2120197A1 (en) * 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
GB9320668D0 (en) 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
US6066331A (en) * 1994-07-08 2000-05-23 Barenholz; Yechezkel Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
AU5702099A (en) * 1998-09-01 2000-03-21 Millennium Pharmaceuticals, Inc. A novel protein related to melanoma-inhibiting protein and uses thereof
EP1025871A1 (en) * 1999-01-28 2000-08-09 F. Hoffmann-La Roche Ag Use of a melanoma inhibiting activity factor (MIA) for cartilage and bone repair
US7435260B2 (en) * 1999-08-13 2008-10-14 Ferree Bret A Use of morphogenetic proteins to treat human disc disease
ES2278648T3 (es) * 1999-12-06 2007-08-16 Warsaw Orthopedic, Inc. Dispositivo para tratar un disco intervertebral.
AU2002331481B2 (en) * 2001-10-03 2008-04-24 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
JP2006518701A (ja) * 2002-05-24 2006-08-17 ネオファーム、インコーポレイティッド カルジオリピン組成物、その製造方法及び使用
US7169405B2 (en) * 2003-08-06 2007-01-30 Warsaw Orthopedic, Inc. Methods and devices for the treatment of intervertebral discs
BRPI0509365B8 (pt) * 2004-03-30 2021-05-25 Ilypsa Inc composição farmacêutica, kit farmacêutico, e, uso da referida composição
EP1778309B1 (en) * 2004-05-21 2010-11-17 Synthes GmbH Replacement of nucleus pulposus using a hydrogel
CA2567405A1 (en) * 2004-05-25 2005-12-08 Stryker Corporation Use of morphogenic proteins for treating cartilage defects
EP1604693A1 (en) * 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
WO2006050327A2 (en) * 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
US20110071056A1 (en) * 2009-09-24 2011-03-24 Rajesh K Saini Degradable Surfactants, Including Degradable Gemini Surfactants, and Associated Methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6242733A (ja) * 1985-08-07 1987-02-24 スミスクライン・ビーチャム・コーポレイション リポソ−ム形成用組成物および形成方法
JPH11514349A (ja) * 1995-09-07 1999-12-07 オッパーバス・ホールディング・ビー・ブイ 核酸デリバリー担体

Also Published As

Publication number Publication date
EP2086507A1 (en) 2009-08-12
PT2081551E (pt) 2013-02-18
RS52706B (sr) 2013-08-30
WO2008040556A1 (en) 2008-04-10
US20090297580A1 (en) 2009-12-03
CN101528197B (zh) 2013-02-13
CY1113934T1 (el) 2016-07-27
EP2086507B1 (en) 2018-11-07
KR20090086397A (ko) 2009-08-12
JP5404402B2 (ja) 2014-01-29
SI2081551T1 (sl) 2013-05-31
RU2009117170A (ru) 2010-11-20
WO2008040557A1 (en) 2008-04-10
US20090285880A1 (en) 2009-11-19
JP5484059B2 (ja) 2014-05-07
CN101528197A (zh) 2009-09-09
JP2010505482A (ja) 2010-02-25
EP2081551A1 (en) 2009-07-29
JP2010505785A (ja) 2010-02-25
ES2400162T3 (es) 2013-04-08
EP2081551B1 (en) 2013-01-23
DK2081551T3 (da) 2013-05-06
US20160220638A1 (en) 2016-08-04
HRP20130328T1 (hr) 2013-05-31
CN101605534A (zh) 2009-12-16
CN102940878A (zh) 2013-02-27
TW200829283A (en) 2008-07-16
TWI455731B (zh) 2014-10-11
ES2708851T3 (es) 2019-04-11
RU2443412C2 (ru) 2012-02-27
CA2664637A1 (en) 2008-04-10
PL2081551T3 (pl) 2013-06-28
CA2664637C (en) 2013-11-12
US9526761B2 (en) 2016-12-27

Similar Documents

Publication Publication Date Title
KR101333279B1 (ko) 약학적 응용을 위한 건조된 재구성 소포 형성
CA2505520C (en) Protein-stabilized liposomal formulations of pharmaceutical agents
JP2792702B2 (ja) 乾燥時に改善された安定性を示すリポソームの調製方法
CA2199004C (en) Preparation of multivesicular liposomes for controlled release of active agents
US9655848B2 (en) Liposomes for in-vivo delivery
US6066331A (en) Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
Kedar et al. Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes
JP2008044962A (ja) 多胞状リポソームへの薬剤封入量の調節
US5576017A (en) Heterovesicular liposomes
JP2001515852A (ja) 多胞状リポソーム中のｉｇｆ−ｉの高封入量製剤および低封入量製剤
CN107206110B (zh) 靶向的充气微囊制剂
US20120100067A1 (en) Solubilisation Method
CA2631243A1 (en) Liposomal compositions
JPH10508578A (ja) 凍結乾燥リポソーム生成物の製造方法
CN114302709A (zh) 包裹腺苷的脂质体
EP0496824B1 (en) Reconstitution method
JP3908776B2 (ja) 細胞への遺伝子導入用組成物
CN121941488A (zh) 冷冻干燥方法
JPS61501686A (ja) リポソ−ム↓−ゲル組成物
WO1991007962A1 (fr) Emulsion de graisse
HK1240506A1 (en) Targeted gas-filled microvesicles formulation
HK1240506B (zh) 靶向的充气微囊制剂
HK40017554A (en) Neuroprotective liposome compositions and methods for treatment of stroke
CA2199018A1 (en) Method of producing a lyophilized liposome product

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20161111

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20171109

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20201121

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20201121